{'52WeekChange': -0.15617532,
 'SandP52WeekChange': 0.0644362,
 'address1': '2200 Pennsylvania Avenue NW',
 'address2': 'Suite 300E',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 10.58,
 'askSize': 1200,
 'averageDailyVolume10Day': 606612,
 'averageVolume': 672246,
 'averageVolume10days': 606612,
 'beta': 0.531092,
 'beta3Year': None,
 'bid': 10.57,
 'bidSize': 900,
 'bookValue': 7.692,
 'category': None,
 'circulatingSupply': None,
 'city': 'Washington',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 10.9,
 'dayLow': 10.51,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 10.104,
 'enterpriseToRevenue': 1.177,
 'enterpriseValue': 279603392,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 11.358571,
 'fiftyTwoWeekHigh': 17.85,
 'fiftyTwoWeekLow': 7.12,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 40419710,
 'forwardEps': 0.01,
 'forwardPE': 1059,
 'fromCurrency': None,
 'fullTimeEmployees': 284,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.03036,
 'heldPercentInstitutions': 0.98002,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/vandapharma.com',
 'longBusinessSummary': 'Vanda Pharmaceuticals Inc., a biopharmaceutical '
                        'company, focuses on the development and '
                        'commercialization of therapies to address high unmet '
                        "medical needs. The company's marketed products "
                        'include HETLIOZ for the treatment of non-24-hour '
                        'sleep-wake disorders; and Fanapt for the treatment of '
                        'schizophrenia. Its products under development include '
                        'HETLIOZ (tasimelteon) for the treatment of jet lag '
                        'disorder, smith-magenis syndrome, pediatric Non-24, '
                        'and delayed sleep phase disorder; FanaptÂ® '
                        '(iloperidone) for the treatment of bipolar disorder '
                        'and a long acting injectable formulation program for '
                        'the treatment of schizophrenia; and Tradipitant '
                        '(VLY-686), a small molecule neurokinin-1 receptor '
                        '(NK-1R) antagonist, for the treatment of atopic '
                        'dermatitis, gastroparesis, and motion sickness. The '
                        "company's products under development also comprise "
                        'VTR-297, a small molecule histone deacetylase '
                        'inhibitor for the treatment of hematologic '
                        'malignancies and with potential use as a treatment '
                        'for various oncology indications; VQW-765, a small '
                        'molecule nicotinic acetylcholine receptor partial '
                        'agonist for the treatment of psychiatric disorders; '
                        'and a portfolio of cystic fibrosis transmembrane '
                        'conductance regulator activators and inhibitors for '
                        'the treatment of dry eye and ocular inflammation, as '
                        'well as for the treatment of secretory diarrhea '
                        'disorders, including cholera. It markets its products '
                        'in the United States, Europe, and Israel. Vanda '
                        'Pharmaceuticals Inc. was incorporated in 2002 and is '
                        'headquartered in Washington, the District of '
                        'Columbia.',
 'longName': 'Vanda Pharmaceuticals Inc.',
 'market': 'us_market',
 'marketCap': 577689792,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_24545059',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 116651000,
 'nextFiscalYearEnd': 1640908800,
 'open': 10.9,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.62,
 'phone': '202 734 3400',
 'previousClose': 11.01,
 'priceHint': 2,
 'priceToBook': 1.3767551,
 'priceToSalesTrailing12Months': 2.432634,
 'profitMargins': 0.49120998,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 10.9,
 'regularMarketDayLow': 10.51,
 'regularMarketOpen': 10.9,
 'regularMarketPreviousClose': 11.01,
 'regularMarketPrice': 10.9,
 'regularMarketVolume': 547008,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 54550500,
 'sharesPercentSharesOut': 0.1142,
 'sharesShort': 6229749,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4976862,
 'shortName': 'Vanda Pharmaceuticals Inc.',
 'shortPercentOfFloat': 0.1421,
 'shortRatio': 7.06,
 'startDate': None,
 'state': 'DC',
 'strikePrice': None,
 'symbol': 'VNDA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 2.109,
 'trailingPE': 5.0213375,
 'twoHundredDayAverage': 11.7090645,
 'volume': 547008,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.vandapharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '20037'}